Modeling of the clinical and economic impact of a risk-sharing agreement supporting a treat-to-target strategy in the management of patients with rheumatoid arthritis in France

References

• Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509
   Web of Science ®Google Scholar
• Kristensen LE, Kapetanovic MC, Gulfe A, et al. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 2008;47:495-9
   PubMed Web of Science ®Google Scholar
• Zink A, Strangfeld A, Schneider M, et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 2006;54:3399-407
   PubMed Web of Science ®Google Scholar
• Hyrich KL, Watson KD, Lunt M, et al. Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology (Oxford) 2011;50:117-23
   PubMed Web of Science ®Google Scholar
• Curtis JR, Jain A, Askling J, et al. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum 2010;40:2-14 e1
   PubMed Web of Science ®Google Scholar
• Katchamart W, Johnson S, Lin HJ, et al. Predictors for remission in rheumatoid arthritis patients: a systematic review. Arthritis Care Res (Hoboken) 2010;62:1128-43
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Keystone EC, Curtis JR, et al. Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial. J Rheumatol 2012;39:1326-33
   PubMed Web of Science ®Google Scholar
• Fransen J, Moens HB, Speyer I, et al. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis 2005;64:1294-8
   PubMed Web of Science ®Google Scholar
• Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007;146:406-15
   PubMed Web of Science ®Google Scholar
• Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90
   PubMed Web of Science ®Google Scholar
• Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9
   PubMed Web of Science ®Google Scholar
• Knevel R, Schoels M, Huizinga TW, et al. Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:987-94
   PubMed Web of Science ®Google Scholar
• Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443-9
   PubMed Web of Science ®Google Scholar
• Stenger AA, Van Leeuwen MA, Houtman PM, et al. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. Br J Rheumatol 1998;37:1157-63
   PubMedGoogle Scholar
• Symmons D, Tricker K, Roberts C, et al. The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis. Health Technol Assess 2005;9:iii-iv, ix–x, 1–78
   PubMed Web of Science ®Google Scholar
• van Tuyl LH, Lems WF, Voskuyl AE, et al. Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial. Ann Rheum Dis 2008;67:1574-7
   PubMed Web of Science ®Google Scholar
• Fechtenbaum M, Md Yusof MY, Emery P. Certolizumab pegol in rheumatoid arthritis: current update. Expert Opin Biol Ther 2014;14:841-50
   PubMed Web of Science ®Google Scholar
• European Medecines Agency. Certolizumab pegol 200 mg solution for injection (Cimzia): Summary of Product Characteristics. 2009
   Google Scholar
• Haute Autorité de Santé. Avis de la Commission de la Transparence; Cimzia 200 mg, solution injectable. 2010
   Google Scholar
• Cook JP, Vernon JA, Manning R. Pharmaceutical risk-sharing agreements. Pharmacoeconomics 2008;26:551-6
   PubMed Web of Science ®Google Scholar
• de Pouvourville G. Risk-sharing agreements for innovative drugs: a new solution to old problems? Eur J Health Econ 2006;7:155-7
   PubMedGoogle Scholar
• Garrison LP, Jr., Towse A, Briggs A, et al. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health 2013;16:703-19
   PubMed Web of Science ®Google Scholar
• Fautrel B, Laurendeau C, Joubert JM, et al. Real world utilization of biological agents in rheumatoid arthritis patients: a French national claims database analysis over the period 2009-2011. Value Health 2013;16:A572-3
   Google Scholar
• Du Pan SM, Dehler S, Ciurea A, et al. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009;61:560-8
   PubMed Web of Science ®Google Scholar
• Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62:22-32
   PubMed Web of Science ®Google Scholar
• Kievit W, Fransen J, Adang EM, et al. Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies. Ann Rheum Dis 2009;68:844-9
   PubMed Web of Science ®Google Scholar
• Hyrich KL, Lunt M, Watson KD, et al. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20
   PubMed Web of Science ®Google Scholar
• Brocq O, Roux CH, Albert C, et al. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease. Joint Bone Spine 2007;74:148-54
   PubMed Web of Science ®Google Scholar
• Fautrel B, Cukierman G, Joubert JM, et al. Characteristics and management of rheumatoid arthritis in France: analysis of a representative French national claims database resulting in an estimated prevalence of 0.35%. Joint Bone Spine. 2015 Dec 8. [Epub ahead of print]
   Google Scholar
• Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39
   PubMed Web of Science ®Google Scholar
• Nam JL, Winthrop KL, van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010;69:976-86
   PubMed Web of Science ®Google Scholar
• Fautrel B, Pham T, Mouterde G, et al. Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis. Joint Bone Spine 2007;74:627-37
   PubMed Web of Science ®Google Scholar
• CEGEDIM. 2013
   Google Scholar
• Aaltonen KJ, Virkki LM, Malmivaara A, et al. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 2012; 7:e30275
   Google Scholar
• Schiff M, Weinblatt ME, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 2014;73:86-94
   PubMed Web of Science ®Google Scholar
• Singh JA, Christensen R, Wells GA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 2009;181:787-96
   PubMed Web of Science ®Google Scholar
• Gaujoux-Viala C, Gossec L, Cantagrel A, et al. Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis. Joint Bone Spine 2014;81:287-97
   PubMed Web of Science ®Google Scholar
• Lopez-Gonzalez R, Leon L, Loza E, et al. Adherence to biologic therapies and associated factors in rheumatoid arthritis, spondyloarthritis and psoriatic arthritis: a systematic literature review. Clin Exp Rheumatol 2015;33:559-69
   PubMed Web of Science ®Google Scholar
• van den Bemt BJ, Zwikker HE, van den Ende CH. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol 2012;8:337-51
   PubMed Web of Science ®Google Scholar
• Launois R, Avouac B, Berenbaum F, et al. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis. J Rheumatol 2011;38:835-45
   PubMed Web of Science ®Google Scholar
• Haute Autorité de la Santé. Avis de la Commission de la Transparence: Simponi. 2012
   Google Scholar
• Haute Authorité de la Santé. Polyarthrite rhumatoïde: recommandations professionnelles. Synthèses des recommandations Septembre 2007. St Denis, 2007
   Google Scholar
• Remy A, Avouac J, Gossec L, et al. Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. Clin Exp Rheumatol 2011;29:96-103
   PubMed Web of Science ®Google Scholar
• Lloyd S, Bujkiewicz S, Wailoo AJ, et al. The effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology (Oxford) 2010;49:2313-21
   PubMed Web of Science ®Google Scholar
• Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210-21
   PubMed Web of Science ®Google Scholar
• Haute Autorité de la Santé. Avis de la Commission de la Transparence: RoActemra. 2010
   Google Scholar
• European Medicines Agency. Draft guideline on clinical investigation of medicinal products other than non-steroidal anti-inflammatory drugs for treatment of rheumatoid arthritis. London: EMA, 2011
   Google Scholar
• Soini EJ, Hallinen TA, Puolakka K, et al. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis. J Med Econ 2012;15:340-51
   PubMedGoogle Scholar
• Saraux A, Gossec L, Goupille P, et al. Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France. Rheumatology (Oxford) 2010;49:733-40
   PubMed Web of Science ®Google Scholar
• Fautrel B, Cukierman G, Joubert JM, et al. Healthcare service utilisation costs attributable to rheumatoid arthritis in France: analysis of a representative national claims database Joint Bone Spine 2016;83:53-56
   Google Scholar
• Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004;43:1252-5
   PubMed Web of Science ®Google Scholar
• Prevoo ML, van Gestel AM, van THMA, et al. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996;35:1101-5
   PubMedGoogle Scholar
• Dougados M, Schmidely N, Le Bars M, et al. Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data. Ann Rheum Dis 2009;68:484-9
   PubMed Web of Science ®Google Scholar
• Gullick NJ, Oakley SP, Zain A, et al. Goal-directed therapy for RA in routine practice is associated with improved function in patients with disease duration up to 15 years. Rheumatology (Oxford) 2012;51:759-61
   PubMed Web of Science ®Google Scholar
• Kim HL, Lee MY, Park SY, et al. Comparative effectiveness of cycling of tumor necrosis factor-alpha (TNF-alpha) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-alpha inhibitor using a Bayesian approach. Arch Pharm Res 2014;37:662-70. http://base-donnees-publique.medicaments.gouv.fr.
   PubMed Web of Science ®Google Scholar
• Keystone E, Heijde D, Mason D, Jr., et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319-29
   PubMed Web of Science ®Google Scholar
• Smolen J, Landewe RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68:797-804
   PubMed Web of Science ®Google Scholar
• Tubach F, Ravaud P, Martin-Mola E, et al. Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study. Arthritis Care Res (Hoboken) 2012;64:1699-707
   PubMed Web of Science ®Google Scholar
• Heiberg T, Kvien TK, Mowinckel P, et al. Identification of disease activity and health status cut-off points for the symptom state acceptable to patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:967-71
   PubMed Web of Science ®Google Scholar
• Hallinen TA, Soini EJ, Eklund K, et al. Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting. Rheumatology (Oxford) 2010;49:767-77
   PubMed Web of Science ®Google Scholar
• Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011;63:573-86
   PubMed Web of Science ®Google Scholar
• Fautrel B, Verstappen SM, Boonen A. Economic consequences and potential benefits. Best Pract Res Clin Rheumatol 2011;25:607-24
   PubMed Web of Science ®Google Scholar
• Sécuité Sociale: l'Assurance Maladie. Base de données des medicaments. 2013
   Google Scholar